International Textbook of Diabetes Mellitus, 4th Ed., Chapter 11 – Incretin physiology in health and disease

References:

1. Moore B, Edie ES, Abram JH: On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. *Biochemical Journal* 1906;1:28 – 38.
2. La Barre J: Sur les possibilitiés d'un traitement du diabete par l'incrétine. *Bulletin de l'Académie royale de médicine de Belgique* 1932;12:620 – 634.
3. Creutzfeldt W:The [pre-]history of the incretin concept. *Regulatory Peptides* 2005;128(2):87–91.
4. Elrick H, Stimmler L, Hlad CJ, Arai Y: Plasma insulin response to oral and intravenous glucose administration. *Journal of Clinical Endocrinology & Metabolism* 1964;24:1076–1082.
5. McIntyre N, Holdsworth CD, Turner DS: Intestinal factors in the control of insulin secretion. *Journal of Clinical Endocrinology & Metabolism* 1965;25:1317 – 1324.
6. Nauck MA, Homberger E, Siegel EG, et al.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. *Journal of Clinical Endocrinology & Metabolism* 1986;63:492–498.
7. Meier JJ, Deacon CF, Schmidt WE, et al.: Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. *Diabetologia* 2007;50(4):806 – 813.
8. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. *Lancet* 1987; 2:1300 – 1304.
9. Meier JJ, Gallwitz B, Siepmann N, et al.: Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. *Diabetologia* 2003;46:798 – 801.
10. Mentis N, Vardarli I, Kothe LD, et al.: GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. *Diabetes* 2011;60(4):1270 – 1276.
11. Meier JJ, Nauck MA: Is the diminished incretin effect in type 2 diabetes just an epiphenomenon of impaired beta-cell function? *Diabetes* 2010;59(5):1117 – 1125.
12. Lindgren O, Carr RD, Deacon CF, et al.: Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. *Journal of Clinical Endocrinology & Metabolism* 2011;96(8):2519 – 2524.
13. Fieseler P, Bridenbaugh S, Nustede R, et al.: Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. *American Journal of Physiology* 1995;268:E949 – 955.
14. Salehi M, Aulinger B, D'Alessio DA: Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. *Diabetes* 2012;61(11):2728 – 2733.

15. Sjolund K, Sanden G, Håkanson R, Sundler F: Endocrine cells in human intestine: an immunocyto chemical study. *Gastroenterology* 1983;85(5):1120 – 1130.
16. Nauck MA, Meier JJ: Incretins and regulation of insulin secretion. In: Seino S, Bell GI (eds.) *Pancreatic Beta Cell in Health and Disease*. Springer, 2008, pp. 335 – 378.
17. Nauck MA, Schmidt WE, Ebert R, et al.: Insulinotropic properties of synthetic gastric inhibitory peptide in man: interactions with glucose, phenylalanin, and cholezystokinin-8. *Journal of Clinical Endocrinology & Metabolism* 1989;69:654 – 662.
18. Nauck MA, Bartels E, Ørskov C, et al.: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. *Journal of Clinical Endocrinology & Metabolism* 1993;76:912 – 917.
19. Vollmer K, Holst JJ, Baller B, et al.: Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. *Diabetes* 2008;57(3):678 – 687.
20. Toft-Nielsen MB, Damholt MB, Madsbad S, et al.: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. *Journal of Clinical Endocrinology & Metabolism* 2001;86:3717 – 3723.
21. Vilsbøll T, Krarup T, Deacon CF, et al.: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. *Diabetes* 2001;50:609 – 613.
22. Ebert R, Creutzfeldt W: Decreased GIP secretion through impairment of absorption. In: Wimersma Greidanus TB (ed.) *Frontiers in Hormone Research*. Basel: S. Karger, 1980, pp. 192 – 201.
23. Parker HE, Habib AM, Rogers GJ, et al.: Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. *Diabetologia* 2009;52(2):289 – 298.
24. Stephens JW, Bodvarsdottir TB, Wareham K, et al.: Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. *Diabetes Research and Clinical Practice* 2011;94(2):199 – 206.
25. Moss CE, Marsh WJ, Parker HE, et al.: Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose- dependent insulinotropic polypeptide from intestinal K cells in rodents. *Diabetologia* 2012;55(11):3094 – 3103.
26. Mortensen K, Petersen LL, Orskov C: Colocalization of GLP-1 and GIP in human and porcine intestine. *Annals of the N Y Academy of Sciences* 2000;921:469 – 472.
27. Holst JJ: Enteroglucagon. *Annual Review of Physiology* 1997;59: 257 – 271.

28. Gribble FM: RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of type 2 diabetes. *Diabetic Medicine* 2008;25(8):889 – 894.
29. Diakogiannaki E, Gribble FM, Reimann F: Nutrient detection by incretin hormone secreting cells. *Physiology & Behavior* 2012; 106(3):387 – 393.
30. Thomas C, Gioiello A, Noriega L, et al.: TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metabolism* 2009; 10(3):167 – 177.
31. Jang HJ, Kokrashvili Z, Theodorakis MJ, et al.: Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. *PNAS* 2007;104(38):15069 – 15074.
32. Gerspach AC, Steinert RE, Schonenberger L, et al.: The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. *American Journal of Physiology - Endocrinology & Metabolism* 2011;301(2):E317 – 325.
33. Ellingsgaard H, Hauselmann I, Schuler B, et al.: Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. *Nature Medicine* 2011; 17(11):1481 – 1489.
34. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. *European Journal of Biochemistry* 1993;214:829 – 835.
35. Deacon CF: Circulation and degradation of GIP and GLP-1. *Hormone and Metabolic Research* 2004;36(11 – 12):761 – 765.
36. Holst JJ, Deacon CF: Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. *Diabetologia* 2005;48:612 – 615. 37
37. Plamboeck A, Holst JJ, Carr RD, Deacon CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. *Diabetologia* 2005;48(9):1882 – 1890.
38. Meier JJ, Nauck MA, Kranz D, et al.: Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. *Diabetes* 2004;53:654 – 662.
39. Deacon CF, Nauck MA, Meier J, et al.: Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. *Journal of Clinical Endocrinology & Metabolism* 2000;85:3575 – 3581.
40. Drucker DJ: The biology of incretin hormones. *Cell Metabolism* 2006;3(3):153 – 165.
41. Nauck MA, Kleine N, Ørskov C, et al.: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. *Diabetologia* 1993;36:741 – 744.
42. Scrocchi LA, Brown TJ, MaClusky N, et al.: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. *Nature Medicine* 1996;2:1254 – 1258.

43. Nauck MA, Heimesaat MM, Behle K, et al.: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. *Journal of Clinical Endocrinology & Metabolism* 2002;87:1239 – 1246.
44. Thorens B: Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. *PNAS* 1992;89:8641 – 8645.
45. Gromada J, Bokvist K, Ding WG, et al.: Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. *Diabetes* 1998;47(1):57–65.
46. Buteau J, Roduit R, Susini S, Prentki M: Glucagon-like peptide-1 promotes DNA synthesis, activates phoshatidylinositol 3-kinase and increases transcriptation factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. *Diabetologia* 1999;42:856–864.
47. Farilla L, Bulotta A, Hirshberg B, et al.: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 2003;144(12): 5149 – 5158.
48. Holz GG, Kuhtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). *Nature* 1993;361:362–365.
49. Kjems LL, Holst JJ, Vølund A, Madsbad S:The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. *Diabetes* 2003;52:380–386.
50. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA: Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. *Diabetes* 2010;59(6):1330 – 1337.
51. Creutzfeldt WO, Kleine N, Willms B,etal.:Glucagono static actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type I diabetic patients. *Diabetes Care* 1996;19:580 – 586.
52. deHeerJ, Rasmussen C, Coy DH, Holst JJ:Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. *Diabetologia* 2008;51(12):2263–2270.
53. Imeryuz N, Yegen BC, Bozkurt A, et al.: Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. *American Journal of Physiology* 1997;273(4 Pt 1):G920 – 927.
54. Wettergren A, Schjoldager B, Mortensen PE, et al.:Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. *Digestive Diseases and Sciences* 1993;38:665–673.
55. Nauck MA, Niedereichholz U, Ettler R, et al.:Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. *American Journal of Physiology - Endocrinology and Metabolism* 1997;273:E 981–988.

56. Meier JJ, Gallwitz B, Salmen S, et al.: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism* 2003;88:2719 – 2725.
57. Schirra J, Goke B: The physiological role of GLP-1 in human: incretin, ileal brake or more? *Regulatory Peptides* 2005;128(2): 109 – 115.
58. Schirra J, Kuwert P, Wank U, et al.: Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. *Proceedings of the Association of American Physicians* 1997;109(1):84 – 97.
59. Schjoldager BT, Mortensen PE, Christiansen J, et al.: GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. *Digestive Diseases and Sciences* 1989;34:703 – 708.
60. Schirra J, Nicolaus M, Woerle HJ, et al.: GLP-1 regulates gastroduodenal motility involving cholinergic pathways. *Neurogastroenterology Motility* 2009;21(6):609 – 618, e21 – 22.
61. Nauck MA: Is glucagon-like peptide 1 an incretin hormone? *Diabetologia* 1999;42:373–379.
62. Meier JJ, Kemmeries G, Holst JJ, Nauck MA: Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. *Diabetes* 2005;54(7):2212 – 2218.
63. Turton MD, O'Shea D, Gunn I, et al.: A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* 1996;379: 69–72.
64. Tang Christensen M, Larsen PJ, Göke R, et al.: Central administra- tion of GLP-1-(7-36) amide inhibits food and water intake in rats. *American Journal of Physiology* 1996;271:R848–856.
65. Hisadome K, Reimann F, Gribble FM, Trapp S: Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius electrical properties of glucagon-like peptide 1 neurons. *Diabetes* 2010;59(8):1890–1898.
66. Ørskov C, Poulsen SS, Møller M, Holst JJ: Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. *Diabetes* 1996;45:832 – 835.
67. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. *Journal of Clinical Investigation* 1998;101:515–520.
68. Verdich C, Flint A, Gutzwiller JP, et al.: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. *Journal of Clinical Endocrinology & Metabolism* 2001;86(9):4382 – 4389.
69. Buteau J, El-Assaad W, Rhodes CJ, et al.: Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. *Diabetologia* 2004;47:806–815. 70

70. Rolin B, Larsen MO, Gotfredsen CF, et al.: The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. *American Journal of Physiology - Endocrinology and Metabolism* 2002;283:E745–752.
71. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 1999;48:2270–2276.
72. Stoffers DA, Kieffer TJ, Hussain MA, et al.: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. *Diabetes* 2000;49:741–748.
73. Ling Z, Wu D, Zambre Y, et al.:Glucagon-like peptide1 receptor signaling influences topography of islet cells in mice. *Virchows Archiv, Pathology* 2001;438(4):382 – 387.
74. Tschen SI, Dhawan S, Gurlo T, Bhushan A: Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. *Diabetes* 2009;58(6):1312 – 1320.
75. Farilla L, Hui H, Bertolotto C, et al.: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. *Endocrinology* 2002;143:4397 – 4408.
76. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet* 2002;359:824 – 830.
77. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 2006;368:1696 – 1705.
78. Yamamoto H, Lee CE, Marcus JN, et al.: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. *Journal of Clinical Investigation* 2002;110:43 – 52.
79. Ban K, Noyan-Ashraf MH, Hoefer J, et al.: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. *Circulation* 2008;117(18):2340 – 2350.
80. Bose AK, Mocanu MM, Carr RD, et al.: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. *Diabetes* 2005;54:146 – 151.
81. Nikolaidis LA, Elahi D, Hentosz T, et al.: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. *Circulation* 2004;110:955 – 961.
82. Ussher JR, Drucker DJ: Cardiovascular biology of the incretin system. *Endocrine Reviews* 2012;33(2):187 – 215.

83. During MJ, Cao L, Zuzga DS, et al.: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. *Nature Medicine* 2003;9(9):1173 – 1179.
84. Meier JJ: GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. *Nature Reviews Endocrinology* 2012;8(12):728 – 742.
85. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B: Gastric inhibitory polypeptide: the neglected incretin revisited. *Regulatory Peptides* 2002;107:1 – 13.
86. Krarup T: Immunoreactive gastric inhibitory polypeptide. *Endocrine Reviews* 1988;9:122 – 133.
87. Meier JJ, Nauck MA: Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. *Best Practice & Research Clinical Endocrinology & Metabolism* 2004;18(4):587 – 606.
88. Miyawaki K, Yamada Y, Ban N, et al.: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nature Medicine* 2002;8:738 – 742.
89. Lacroix A, Bolté E, Tremblay J, et al.: Gastric inhibitory polypeptide-dependent cortisol hypersecretion: a new cause of Cushing's Syndrome. *New England Journal of Medicine* 1992;327: 974 – 980.
90. Rehfeld JF, Agersnap M: Unsulfated cholecystokinin: an overlooked hormone? *Regulatory Peptides* 2012;173(1 – 3):1 – 5.
91. Schmidt WE, Creutzfeldt W, Schleser A, et al.: Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide. *American Journal of Physiology* 1991; 260:G197 – 206.
92. Rehfeld JF: Gastrointestinal hormones. *International Review of Physiology* 1979;19:291 – 321.
93. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. *Diabetologia* 1986;29:46 – 54.
94. Meier JJ, Nauck MA: Incretins and the development of type 2 diabetes. *Current Diabetes Reports* 2006;6(3):194 – 201.
95. Nauck MA, Baller B, Meier JJ: Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. *Diabetes* 2004;53(Suppl 3):S190 – 196.
96. Nauck MA, Vardarli I, Deacon CF, et al.: Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? *Diabetologia* 2011;54(1):10 – 18.
97. Nauck MA, Heimesaat MM, Ørskov C, et al.: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *Journal of Clinical Investigation* 1993;91: 301 – 307.
98. Creutzfeldt W: The incretin concept today. *Diabetologia* 1979; 16:75 – 85.